SOURCE: Lipid Sciences, Inc.

April 18, 2008 08:30 ET

Lipid Sciences Presents HDL Mimetic Peptide Data at Arteriosclerosis, Thrombosis, and Vascular Biology Annual Conference

New Anti-Inflammatory Data Presented

PLEASANTON, CA--(Marketwire - April 18, 2008) - Lipid Sciences, Inc. (NASDAQ: LIPD) presented new anti-inflammatory data supporting the Company's HDL Mimetic Peptide development program at the Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB) Annual Conference 2008 in Atlanta, Georgia. The presentation entitled, "An ApoA-I Mimetic Peptide LSI-518P Exhibits ABCA1 Specific Efflux and Anti-Inflammatory Properties" was made on April 17, 2008 by Dr. H. Bryan Brewer, Jr., Chief Scientific Director of Lipid Sciences.

The design objective of Lipid Sciences' innovative HDL Mimetic Peptide development program is to develop a drug that mimics the two principal properties of HDL and its major protein component, ApoA-I -- simultaneous reduction of inflammation and reduction in atherosclerotic plaque. Atherosclerosis is characterized by both inflammation and the build-up of plaque. As demonstrated in this presentation, LSI-518P exhibits anti-inflammatory properties as shown by statistically significant reduction in expression of endothelial cell adhesion molecules, VCAM-1 (p ‹ 0.02) and ICAM-1 (p ‹ 0.01), on human coronary artery cells comparable to that of ApoA-I.

In addition, the Company's lead HDL Mimetic Peptide candidate, LSI-518P, has already demonstrated the ability to reduce proximal aortic atherosclerosis by 20% after 4 weeks of treatment (p=.106), and by 32% (p=.01) after 8 weeks of treatment when compared to a placebo (saline) group in a well-accepted, ApoE knockout mouse model. The combination of these important results -- targeting inflammation and plaque build-up -- makes LSI-518P an ideal HDL mimetic peptide candidate with the potential to be an effective therapeutic agent for HDL therapy in patients with cardiovascular disease.

The abstract related to this presentation will be available in the May 2008 online edition of the American Heart Association (AHA) Journal, Arteriosclerosis, Thrombosis, and Vascular Biology. Both the abstract and the poster associated with this presentation have been added to our website, under the Scientific Abstracts and Publications heading.

About ATVB Annual Conference

This prestigious annual conference focuses on new research opportunities in arteriosclerosis, thrombosis, and vascular biology. It includes special lectures, discussion, and oral and poster presentations. The audience consists of scientists/clinicians in the areas of cardiovascular research, molecular/cellular biology, clinical cardiology, physiology, immunology, genetics, cardiovascular surgery, hematology and endocrinology.

Lipid Sciences, Inc. is a development-stage biotechnology company engaged in the research and development of products and processes intended to treat major medical indications, in which lipids, or fat components, play a key role. The Company's HDL Therapy platform (HDL Mimetic Peptides and HDL Selective Delipidation) aims to develop treatments to reverse atherosclerosis, a systemic disease of the blood vessels caused by the build-up of cholesterol-filled plaques in the vascular system and, most critically, in the coronary arteries. Regression of such plaques may have a major impact on reducing the risk of acute coronary events. The Company's Viral Immunotherapy platform focuses on the removal of the lipid coatings from lipid-enveloped viruses and other lipid-containing infectious agents by applying Lipid Sciences' proprietary delipidation technologies. The Company believes that removing the virus' protective lipid coating enhances the processing and presentation of viral proteins to stimulate the body's immune system to effectively fight the disease. Conditions that could potentially be impacted by these technologies include HIV, Hepatitis B, and Hepatitis C. In addition, Lipid Sciences believes that this Viral Immunotherapy platform also has applicability to a wide range of viruses impacting animal health -- a diverse market with diseases affecting both food and companion animals.

Forward-Looking Statements: This release contains forward-looking statements concerning plans, objectives, goals, strategies, study results, anticipations, expectations, future events or performance as well as all other statements that are not statements of historical fact. The forward-looking statements contained in this release reflect our current beliefs and expectations on the date of this release. Actual results, performance or outcomes may differ materially from what is expressed in the forward-looking statements. Readers should refer to the documents filed by us with the SEC, specifically the most recent reports on Form 10-K and Form 10-Q which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. In addition to those risk factors, other factors that could cause actual results to differ materially include the following: our inability to obtain adequate funds; our technologies not proving to be safe or effective; our inability to obtain regulatory approval of our technologies, which are only in the clinical development stage; delay or failure to complete clinical studies; our dependence on our license agreement with Aruba International B.V.; our reliance on collaborations with strategic partners and consultants; our reliance on key suppliers to provide the material necessary to conduct successful pre-clinical and clinical studies; competition in our industry, including the development of new products by others that may provide alternative or better therapies; failure to secure and enforce our intellectual property rights; risks associated with use of biological and hazardous materials; acceptance of our potential products by healthcare providers and patients; and our dependence on key personnel.

This release should be read in conjunction with the consolidated financial statements and notes thereto included in our most recent reports on Form 10-K and Form 10-Q. Copies are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at Lipid Sciences assumes no obligation to update the forward-looking statements included in this document.

Press releases for Lipid Sciences, Inc. are available on our website: To receive the Company's press releases via email, please contact:

Contact Information

    Deborah S. Lorenz
    Vice President, Investor Relations and
    Corporate Communications
    Lipid Sciences, Inc.
    Email Contact